The recent safety update led Kyowa Kirin and Amgen to conclude potential risks may outweigh benefits for patient populations.

Prurigo nodularis is not only intensely itchy, painful and uncomfortable, it can also take a profound toll on sleep, emotional wellbeing, and daily functioning. That’s why achieving sustained, ...

Newark, New Castle, USA, April 19, 2023 (GLOBE NEWSWIRE) -- According to a recent Growth Plus Reports assessment, the Prurigo Nodularis Treatment Market is estimated to reach US$ 3.40 billion by 2031, ...

Kyowa Kirin on Tuesday said it is discontinuing all ongoing trials of its experimental drug to treat ​skin conditions after ...

Galderma announces positive data from OLYMPIA open-label extension study of Nemluvio in moderate-to-severe prurigo nodularis: Zug, Switzerland Monday, March 2, 2026, 15:00 Hrs [IS ...

San Diego — Nemolizumab, the first-in-class inhibitor of interleukin-31 (IL-31), a neuroimmune cytokine linked to the promotion of pruritis and inflammation, continues to show good efficacy and safety ...

Prurigo nodularis (PN) is extremely itchy skin that leads to a bumpy rash. The rash appears as the result of repeated scratching, picking, or rubbing of the itchy areas of the skin. There isn’t one ...

Prurigo nodularis (PN) is a long-lasting skin condition that causes very itchy, hard bumps, often all over the body. The itch can be so intense that people scratch until the skin breaks, leading to ...

Nemolizumab (Mitchga) is gearing up to be a potential new treatment for prurigo nodularis, with further phase 3 data supporting its efficacy and safety reported this month at the annual meeting of the ...

Demonstrates Long-Term Disease Control In Prurigo Nodularis Up To Three Years - AETOS....(BUSINESS WIRE )--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study inv ...